Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 14/20 | 0.49 |
| ▸ | MLYCD | O95822 | 2/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.45 |
| ▸ | JAK2 | O60674 | 1/20 | 0.44 |
| ▸ | JAK1 | P23458 | 1/20 | 0.44 |
| ▸ | TYK2 | P29597 | 1/20 | 0.44 |
| ▸ | JAK3 | P52333 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | RORA | P35398 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18281161 | 0.81 | RORC (0.58) | RORCMLYCDKCNH2SMN1; SMN2 | |
| SCHEMBL18281148 | 0.78 | RORC (0.43) | RORCMLYCDKCNH2JAK2JAK1 | |
| SCHEMBL18275177 | 0.78 | RORC (0.59) | RORCMLYCDKCNH2 | |
| SCHEMBL20258321 | 0.75 | RORC (0.47) | RORCMLYCDSMN1; SMN2LMNA | |
| SCHEMBL18281166 | 0.75 | RORC (0.55) | RORCKCNH2 | |
| SCHEMBL16799959 | 0.74 | RORC (0.76) | RORCKCNH2RORA | |
| SCHEMBL18281158 | 0.73 | RORC (0.55) | RORCKCNH2 | |
| SCHEMBL18151715 | 0.72 | RORC (0.65) | RORCSMN1; SMN2RORALMNA | |
| SCHEMBL18275170 | 0.71 | RORC (0.51) | RORCMLYCDKCNH2JAK2JAK1 | |
| SCHEMBL18275198 | 0.71 | RORC (0.56) | RORCKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3319942-B1 | ROR-GAMMA MODULATORS | LEAD PHARMA B V (NL) | 2020-03-11 | — | — | EP | disclosed |
| US-20190040012-A1 | ROR GAMMA (RORY) MODULATORS | LEAD PHARMA HOLDING B.V. (NL) | 2019-02-07 | — | — | US | disclosed |
| US-10118895-B2 | ROR gamma (RORγ) modulators | LEAD PHARMA HOLDING B.V. (NL) | 2018-11-06 | — | — | US | disclosed |
| US-20180141909-A1 | ROR GAMMA (RORY) MODULATORS | LEAD PHARMA HOLDING B.V. (NL) | 2018-05-24 | — | — | US | disclosed |
| EP-3319942-A1 | ROR GAMMA (RORY) MODULATORS | Lead Pharma Holding B.V. (NL) | 2018-05-16 | — | — | EP | disclosed |
| WO-2016193468-A1 | ROR GAMMA (RORY) MODULATORS | LEAD PHARMA CEL MODELS IP B.V. (NL) | 2016-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190040012-A1 | ROR GAMMA (RORY) MODULATORS | RORC, RORA, RORB | RORC 1/4885MLYCD 4734/4885KCNH2 2115/4885 |
| US-20180141909-A1 | ROR GAMMA (RORY) MODULATORS | RORC, RORA, RORB | RORC 1/4885MLYCD 4633/4885KCNH2 1767/4885 |
| US-10118895-B2 | ROR gamma (RORγ) modulators | RORC, RORA, RORB | RORC 1/4885MLYCD 4680/4885KCNH2 1819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.